N1 -(4-(5-(CYCLOPROPYLMETHYL)-1 -METHYL-1 H-PYRAZOL-4-YL)PYRIDIN-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS CK1 AND/OR IRAKI INHIBITORS FOR TREATING CANCER
Application/Publication number:
18
705024
Date:
2018-01-30
Applicant(s):
THE HEBREW UNIVERSITY OF JERUSALEM
N1 -(4-(5-(CYCLOPROPYLMETHYL)-1 -METHYL-1 H-PYRAZOL-4-YL)PYRIDIN-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS CK1 AND/OR IRAKI INHIBITORS FOR TREATING CANCER
Application/Publication number:
18
705024
Date:
2018-01-30
Applicant(s):
THE HEBREW UNIVERSITY OF JERUSALEM
N1 -(4-(5-(CYCLOPROPYLMETHYL)-1 -METHYL-1 H-PYRAZOL-4-YL)PYRIDIN-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS CK1 AND/OR IRAKI INHIBITORS FOR TREATING CANCER
Application/Publication number:
18
705024
Date:
2018-01-30
Applicant(s):
THE HEBREW UNIVERSITY OF JERUSALEM
HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE
Application/Publication number:
19
708681
Date:
2019-02-07
Applicant(s):
THE HEBREW UNIVERSITY OF JERUSALEM
HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE
Application/Publication number:
19
708681
Date:
2019-02-07
Applicant(s):
THE HEBREW UNIVERSITY OF JERUSALEM
HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE
Application/Publication number:
19
708681
Date:
2019-02-07
Applicant(s):
THE HEBREW UNIVERSITY OF JERUSALEM
